Medicxi

Medicxi is an international investment firm focused on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

Medicxi is currently investing out of its most recent fund, Medicxi III, and continues to manage the Index Ventures life sciences portfolio. GlaxoSmithKline, Johnson & Johnson Innovation - JJDC, Inc., Novartis and Verily (an Alphabet company) have invested in Medicxi funds.

Fund information

Investment areas

Life Science Their mission is to bring novel therapies to patients in need. They do this by creating, investing and supporting biotech companies along the full drug development continuum, from discovery stage all the way to pivotal studies and registration. Experience has guided our investment approach to focus on clear product visions with the backing of entrepreneurial scientists and seasoned drug hunters, borne out of novel biological insights.

Other information

They strive to minimize complex governance structures and processes that can fetter innovation and create headwinds against scientific breakthroughs: virtual companies and stepwise 'asset-centric' financing can provide a conducive environment for early-stage innovation. At the early stages, They help start companies under our pioneering asset-centric model and support their development from scientific insight to early clinical studies and Proof-of-Concept (PoC). Their late-stage activity is focused on supporting companies that have successfully reached clinical PoC and want to continue building value by developing their compounds independently through pivotal studies, regulatory approvals and launch. Strong impact on unmet medical needs and the healthy financial returns associated with such significant innovation are the common goals they passionately share with the entrepreneurs we back

Ways of communication
https://www.medicxiventures.com/contact

https://www.medicxiventures.com/contact Press Enquiries press@medicxi.com Investor Enquiries investor@medicxi.com General Enquiries info@medicxi.com